Related Experiment Videos
Is chronic long-term inhibition of gastric secretion really dangerous?
1Ninewells Hospital, Dundee, Scotland.
Abstract:
Powerful gastric secretion inhibitors produce cancer in their target organ, the stomach, in experimental animals. The possible mechanisms of the carcinogenic effect are discussed under the headings of the potential noxious change in the gastric luminal contents, as is the possibility that the drugs act as epigenetic or genotoxic carcinogens. Whatever the mechanisms of the drug-induced carcinogenesis, it is clear that there is a toxicologic hazard, which must be assessed rationally and not by means of sophistry. Until the dangers posed by powerful gastric secretory inhibitors to man have been better evaluated, these drugs must not be used for treatment other than of patients with gastrinomas.
Insights
Powerful gastric secretion inhibitors cause stomach cancer in animal studies. These drugs pose a toxicologic hazard and should only be used for gastrinomas until human risks are better understood.
Area of Science:
- Gastroenterology
- Toxicology
- Oncology
Background:
- Powerful gastric secretion inhibitors are used in treating certain gastrointestinal conditions.
- These medications target the stomach's acid-producing cells.
Purpose of the Study:
- To discuss the potential carcinogenic effects of powerful gastric secretion inhibitors.
- To explore the mechanisms behind drug-induced stomach cancer in experimental models.
Main Methods:
- Review of existing literature on gastric secretion inhibitors and carcinogenicity.
- Analysis of potential mechanisms including changes in gastric luminal contents and epigenetic/genotoxic effects.
Main Results:
- Powerful gastric secretion inhibitors induced cancer in the stomachs of experimental animals.
- Potential mechanisms involve alterations in gastric contents or direct genotoxic/epigenetic actions.
Conclusions:
- A significant toxicologic hazard exists with these drugs.
- Further evaluation of human risks is necessary before broader clinical application.
- Current use should be restricted to patients with gastrinomas.